par Loi, Sherene 
;Michiels, Stefan ;Salgado, Roberto;Sirtaine, Nicolas;Jose, Vinu ;Fumagalli, Debora ;Kellokumpu-Lehtinen, P-L;Bono, Petri;Kataja, Vesa;Desmedt, Christine ;Piccart-Gebhart, Martine ;Loibl, Sibylle;Denkert, Carsten;Smyth, M J;Joensuu, Heikki;Sotiriou, Christos
Référence Annals of oncology
Publication Publié, 2014-03
;Michiels, Stefan ;Salgado, Roberto;Sirtaine, Nicolas;Jose, Vinu ;Fumagalli, Debora ;Kellokumpu-Lehtinen, P-L;Bono, Petri;Kataja, Vesa;Desmedt, Christine ;Piccart-Gebhart, Martine ;Loibl, Sibylle;Denkert, Carsten;Smyth, M J;Joensuu, Heikki;Sotiriou, Christos Référence Annals of oncology
Publication Publié, 2014-03
Article révisé par les pairs
| Résumé : | We have previously shown the prognostic importance of tumor infiltrating lymphocytes (TILs) in newly-diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+). |
